Apollon Wealth Management LLC Acquires 4,114 Shares of Stryker Co. (NYSE:SYK)

Apollon Wealth Management LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 70.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,964 shares of the medical technology company’s stock after purchasing an additional 4,114 shares during the quarter. Apollon Wealth Management LLC’s holdings in Stryker were worth $2,984,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Bremer Bank National Association increased its holdings in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after acquiring an additional 34 shares during the period. Simon Quick Advisors LLC raised its holdings in Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after purchasing an additional 34 shares in the last quarter. Consolidated Portfolio Review Corp lifted its position in shares of Stryker by 3.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after buying an additional 34 shares during the last quarter. FourThought Financial Partners LLC boosted its holdings in shares of Stryker by 3.3% in the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after buying an additional 34 shares in the last quarter. Finally, MBL Wealth LLC raised its stake in shares of Stryker by 4.6% during the 4th quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock worth $255,000 after acquiring an additional 37 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

SYK traded up $6.64 during midday trading on Tuesday, hitting $332.14. 1,331,236 shares of the company traded hands, compared to its average volume of 1,332,736. The company has a market capitalization of $126.53 billion, a price-to-earnings ratio of 37.77, a PEG ratio of 2.56 and a beta of 0.91. The business has a 50 day simple moving average of $346.45 and a two-hundred day simple moving average of $318.37. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. Stryker’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.14 EPS. On average, equities analysts forecast that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Wednesday, March 27th. Stryker’s payout ratio is 36.53%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SYK. Roth Mkm raised their price objective on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Stifel Nicolaus boosted their target price on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a research note on Wednesday, January 31st. Robert W. Baird lifted their price target on Stryker from $367.00 to $378.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their target price for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $365.94.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.